000504 南华生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.23011.466-8.034-20.795-81.291
总资产报酬率 ROA (%)0.6403.604-2.877-4.253-2.055
投入资产回报率 ROIC (%)0.7824.572-4.413-8.426-6.075

边际利润分析
销售毛利率 (%)10.01022.07067.41668.06364.792
营业利润率 (%)-0.6714.820-15.481-33.419-13.052
息税前利润/营业总收入 (%)0.6655.151-15.686-26.025-4.978
净利润/营业总收入 (%)0.2924.340-17.795-34.198-14.704

收益指标分析
经营活动净收益/利润总额(%)190.58964.45616.19646.05332.101
价值变动净收益/利润总额(%)-74.54939.088-17.662-2.1330.255
营业外收支净额/利润总额(%)2.905-1.6490.180-2.246-21.290

偿债能力分析
流动比率 (X)1.4551.3551.3161.4480.915
速动比率 (X)1.3311.3211.2041.4240.905
资产负债率 (%)59.27763.95153.63260.50385.509
带息债务/全部投入资本 (%)57.33662.94644.27640.10585.157
股东权益/带息债务 (%)65.96251.823119.935141.4677.621
股东权益/负债合计 (%)52.02141.90272.69055.0542.961
利息保障倍数 (X)0.49112.58188.422-3.907-0.861

营运能力分析
应收账款周转天数 (天)109.219154.971351.848371.056318.839
存货周转天数 (天)24.41229.278183.74362.46738.635